Women who are obese continue to have higher levels of oestrogen than women of normal weight even after treatment with hormone-suppressing drugs, raising the possibility that they might benefit from changes to their treatment.
The study, led by a team at The Institute of Cancer Research in London and The Royal Marsden NHS Foundation Trust, found hormone-suppressing drugs did markedly reduce oestrogen levels in obese women – but that their levels of oestrogen remained more than double those of women of normal weight.
The research, which is published today in the Journal of Clinical Oncology, could lead to improvements in doctors' ability to select the most appropriate treatment for overweight and obese women. But scientists stressed the effect of obesity was modest and that women taking breast cancer treatment should not be concerned by the findings.
Over three-quarters of breast cancers require oestrogen to grow, so one of the main ways of treating the disease is by blocking the hormone's production or action. Obese women have higher levels of oestrogen than women of normal weight, and the new findings show that although their oestrogen levels are markedly reduced with hormone-suppressing drugs called aromatase inhibitors, the levels are higher during treatment than those in similarly treated normal weight women.
Senior author Professor Mitch Dowsett, a team leader in the Breakthrough Breast Cancer Research Centre at The Institute of Cancer Research and head of the academic department of biochemistry at The Royal Marsden, said: "We found that women with higher BMIs had more oestrogen remaining in their blood after treatment than healthy-weight women, which is consistent with previous suggestions that aromatase inhibitors might be slightly less effective in these women.
"Our findings are based on laboratory studies, so we would need to carry out clinical trials to tell us whether women with a higher BMI would benefit from changes to their treatment. Women with higher BMIs should certainly not be alarmed by this finding or stop taking their treatment. Our study takes us a step closer to understanding which of the treatment options available might be the most suitable for individual women."
Professor Dowsett and colleagues set out to probe a recent study that indicated the aromatase inhibitor anastrozole was no more effective than older-style tamoxifen in women with higher BMI, unlike in the general population where it is clearly more effective.
One possible explanation is that tamoxifen is more effective in overweight women, but the team wanted to investigate the other possibility – that in these women aromatase inhibitors are less effective.
The scientists examined two aromatase inhibitors: anastrozole and a more potent drug called letrozole. The study included 54 postmenopausal women with oestrogen receptor positive breast cancer who were treated at the Edinburgh Breast Unit with either three months of adjuvant anastrozole followed by three months of letrozole, or the drugs in the opposite sequence. Data on body mass index (BMI) and oestrogen levels – before and after treatment with the first drug, as measured by levels of estradiol and oestrone sulphate in the blood - were available for 44 patients.
The study found that, prior to treatment, women with higher BMIs had higher oestrogen levels – those with BMIs from 30 to 35 had around three times more plasma oestrogen than those with BMIs of less than 25.
After treatment with letrozole, women with BMIs of 30 to 35 still had levels of plasma oestrogen nearly three times as high as for healthy-weight women. The same trend was found for anastrozole, but did not reach statistical significance.
Professor Alan Ashworth, Chief Executive of The Institute of Cancer Research, said: "Aromatase inhibitors have played an increasing role in breast cancer treatment over the past decade, so it is important to understand the factors that affect how well they work in individual women in order to allow doctors to choose the best possible drug from the range available."
The study received funding from Breakthrough Breast Cancer and through the National Institute for Health Research's Biomedical Research Centre for Cancer at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust.
Media Contact: ICR Science Communications Manager Jane Bunce on 0207 153 5106
Notes to editors:
In the UK, the healthy weight range is considered 18.5 to 25, between 25 and 30 is overweight and above 30 is obese.
"Suppression of Plasma Estrogen Levels by Letrozole and Anastrozole Is Related to Body Mass Index in Patients With Breast Cancer" with corresponding author Mitch Dowsett publishes online first in the Journal of Clinical Oncology on Monday 16 July 2012
The Institute of Cancer Research (ICR) is one of the world's most influential cancer research institutes.
Scientists and clinicians at the ICR are working every day to make a real impact on cancer patients' lives. Through its unique partnership with The Royal Marsden Hospital and 'bench-to-bedside' approach, the ICR is able to create and deliver results in a way that other institutions cannot. Together the two organisations are rated in the top four cancer centres globally.
The ICR has an outstanding record of achievement dating back more than 100 years. It provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease. Today it leads the world at isolating cancer-related genes and discovering new targeted drugs for personalised cancer treatment.
As a college of the University of London, the ICR provides postgraduate higher education of international distinction. It has charitable status and relies on support from partner organisations, charities and the general public.
The ICR's mission is to make the discoveries that defeat cancer. For more information visit www.icr.ac.uk
The Royal Marsden NHS Foundation Trust
The Royal Marsden opened its doors in 1851 as the world's first hospital dedicated to cancer diagnosis, treatment, research and education.
Today, together with its academic partner, The Institute of Cancer Research (ICR), it is the largest and most comprehensive cancer centre in Europe treating over 44,000 patients every year. It is a centre of excellence with an international reputation for groundbreaking research and pioneering the very latest in cancer treatments and technologies. The Royal Marsden also provides community services in the London boroughs of Sutton and Merton and in June 2010, along with the ICR, the Trust launched a new academic partnership with Mount Vernon Cancer Centre in Middlesex.
Since 2004, the hospital's charity, The Royal Marsden Cancer Charity, has helped raise over £50 million to build theatres, diagnostic centres, and drug development units.
Prince William became President of The Royal Marsden in 2007, following a long royal connection with the hospital.
For more information, visit www.royalmarsden.nhs.uk
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.